CSL Akcia

CSL Goodwill

Delisted·19. 6. 2026

Obchodný fond spoločnosti CSL (CSL.AX) k 12. 8. 2026 je 8,07 Miliarda USD. V predchádzajúcom roku Obchodný fond bolo 8,08 Miliarda USD — zmena o -0,17 % (nižšie).

Goodwill

8,07 MiliardaUSD

YoY

-0,17%

Naposledy aktualizované:

Obchodný fond spoločnosti CSL je 2026 8,07 Miliarda USD. Obchodný fond spoločnosti CSL bolo 2025 8,08 Miliarda USD. Klesá teda o -0,17% nižšie oproti predchádzajúcemu roku.
Access this data via the Eulerpool API

CSL Analýza akcií

Čo robí CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL je jednou z najobľúbenejších spoločností na Eulerpool.

Často kladené otázky o akcii CSL

Obchodný fond spoločnosti CSL je 8,07 Miliarda USD v roku 2026.

Obchodný fond spoločnosti CSL sa zmenil z 8,08 Miliarda USD na 8,07 Miliarda USD, čo predstavuje zmenu -0,17 %. Hodnota je nižšie ako v predchádzajúcom roku.

Na Eulerpool nájdete kompletnú historickú evolúciu CSL Obchodný fond od roku 2006 – s ročnými hodnotami, grafmi a detailnou analýzou.

Obchodný fond je prirážka zaplatená nad spravodlivou trhovou hodnotou pri akvizícii. Predstavuje nehmotný majetok, ako je rozpoznávateľnosť značky, vzťahy so zákazníkmi a duševné vlastníctvo.

Obchodný fonds USD je kľúčovým faktorom pre investorov. Zmeny v tejto metrike môžu signalizovať zlepšovanie alebo zhoršovanie základných ukazovateľov, čo priamo vplýva na cenu akcie. Na Eulopoole môžete sledovať Obchodný fonds CSL historicky a v reálnom čase.

Access this data via the Eulerpool API

Bilancia — CSL

Všetky kľúčové ukazovatele — CSL